101 related articles for article (PubMed ID: 8355178)
21. Intracoronary papaverine induced myocardial lactate production in patients with angiographically normal coronary arteries.
Takeuchi M; Nohtomi Y; Kuroiwa A
Cathet Cardiovasc Diagn; 1996 Oct; 39(2):126-30. PubMed ID: 8922310
[TBL] [Abstract][Full Text] [Related]
22. Intravenous Procainamide for Predicting the Response of Sustained Ventricular Tachycardia to Type III Antiarrhythmic Drugs.
Snow JS; Cohen MB; Jadonath RL; Cohen TJ
J Invasive Cardiol; 1997 Jan; 9(1):40-44. PubMed ID: 10762873
[TBL] [Abstract][Full Text] [Related]
23. Amiodarone is poorly effective for the acute termination of ventricular tachycardia.
Marill KA; deSouza IS; Nishijima DK; Stair TO; Setnik GS; Ruskin JN
Ann Emerg Med; 2006 Mar; 47(3):217-24. PubMed ID: 16492484
[TBL] [Abstract][Full Text] [Related]
24. Ventricular tachyarrhythmias in regional myocardial hyperkalemia: efficacy of three antiarrhythmic agents.
Ettinger PO; Moore RJ; Calabro J; Oldewurtel HA; Regan TJ
J Electrocardiol; 1980 Apr; 13(2):153-7. PubMed ID: 7365356
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of intravenous procainamide as used during acute electropharmacologic testing.
Morady F; Kou WH; Schmaltz S; Annesley T; De Buitleir M; Nelson SD; Kushner JA
Am J Cardiol; 1988 Jan; 61(1):93-8. PubMed ID: 3337024
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide.
Windle J; Prystowsky EN; Miles WM; Heger JJ
Clin Pharmacol Ther; 1987 Jun; 41(6):603-10. PubMed ID: 3581646
[TBL] [Abstract][Full Text] [Related]
27. Modification of ventricular tachycardia by procainamide in patients with coronary artery disease.
Engel TR; Meister SG; Luck JC
Am J Cardiol; 1980 Dec; 46(6):1033-8. PubMed ID: 7446417
[TBL] [Abstract][Full Text] [Related]
28. Hemodynamic effects of combined treatment with lignocaine, procainamide and practolol in acute myocardial infarction.
Nordlander R; Nyquist O
Cardiology; 1980; 66(1):27-42. PubMed ID: 7388852
[TBL] [Abstract][Full Text] [Related]
29. Myocardial uptake of ouabain in intact dog and man.
Selden R; Neill WA
J Pharmacol Exp Ther; 1975 Jun; 193(3):951-62. PubMed ID: 1151741
[TBL] [Abstract][Full Text] [Related]
30. Whole blood versus plasma measurements of glutamate and alanine across the human myocardium.
Thomassen AR; Nielsen TT; Bagger JP; Henningsen P
Scand J Clin Lab Invest; 1987 May; 47(3):293-300. PubMed ID: 3589494
[TBL] [Abstract][Full Text] [Related]
31. Relationship between plasma levels of procainamide, suppression of premature ventricular complexes and prevention of recurrent ventricular tachycardia.
Myerburg RJ; Kessler KM; Kiem I; Pefkaros KC; Conde CA; Cooper D; Castellanos A
Circulation; 1981 Aug; 64(2):280-90. PubMed ID: 7249296
[TBL] [Abstract][Full Text] [Related]
32. Plasma and myocardial tissue concentrations of UM-272 (N,N-dimethylpropranolol) after oral administration in dogs.
Patterson E; Stetson P; Lucchesi BR
J Pharmacol Exp Ther; 1980 Aug; 214(2):449-53. PubMed ID: 7391989
[TBL] [Abstract][Full Text] [Related]
33. Myocardial disposition and cardiac pharmacodynamics of verapamil in the dog.
Keefe DL; Kates RE
J Pharmacol Exp Ther; 1982 Jan; 220(1):91-6. PubMed ID: 7053427
[TBL] [Abstract][Full Text] [Related]
34. Effect of pH on the myocardial uptake and pharmacodynamics of propafenone in the isolated rabbit heart.
Gillis AM; Kates RE
J Cardiovasc Pharmacol; 1988; 12(5):526-34. PubMed ID: 2468051
[TBL] [Abstract][Full Text] [Related]
35. Effects of procainamide on the dispersion of recovery of excitability during coronary occlusion.
Levites R; Haft JI; Calderon J; Venkatachalapathy
Circulation; 1976 Jun; 53(6):982-4. PubMed ID: 1269135
[TBL] [Abstract][Full Text] [Related]
36. Acute myocardial uptake of digoxin in humans: correlation with hemodynamic and electrocardiographic effects.
Powell AC; Horowitz JD; Hasin Y; Syrjanen ML; Horomidis S; Louis WJ
J Am Coll Cardiol; 1990 May; 15(6):1238-47. PubMed ID: 2329227
[TBL] [Abstract][Full Text] [Related]
37. Relationship between the pharmacokinetics and pharmacodynamics of procainamide.
Galeazzi RL; Benet LZ; Sheiner LB
Clin Pharmacol Ther; 1976 Sep; 20(3):278-89. PubMed ID: 954350
[TBL] [Abstract][Full Text] [Related]
38. Massive doses of procainamide for ventricular tachyarrhythmias due to myocardial infarction.
Mattiasson I; Hanson A; Johansson BW
Acta Med Scand; 1978; 204(1-2):27-34. PubMed ID: 685726
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical localization of procainamide in normal, ischemic, and necrotic canine myocardium during acute experimental myocardial infarction.
Siegel RJ; Fealy M; Edwalds G; Karagueuzian H; Fishbein MC
Am Heart J; 1987 Jun; 113(6):1383-9. PubMed ID: 3591607
[TBL] [Abstract][Full Text] [Related]
40. Identification of desethyl procainamide in patients: a new metabolite of procainamide.
Ruo TI; Morita Y; Atkinson AJ; Henthorn T; Thenot JP
J Pharmacol Exp Ther; 1981 Feb; 216(2):357-62. PubMed ID: 6162026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
